Table 2
Open in new tab

Respiratory syncytial virus vaccines in phase III clinical trials and in the approval process in older patients

NameInventorVaccine typeTarget groupDevelopment statusVaccine efficacy
mRNA-1345ModernamRNA vaccineAdults ≥ 60 yearsPhase 3, submit for approval in the second half of 2023Phase 3 study: 83.7%
RSVPreF3GSKAdjuvanted Protein-based vaccineAdults ≥ 60 yearsFood and Drug Administration (FDA) approval May 2023, European Commission approval June 2023Phase 3 study: overall 82.6%, older adults with underlying medical condition 94.6%101
RSVpreFPfizerProtein-based vaccineAdults ≥ 60 yearsPhase 3, FDA approval, European Commission approval August 2023Interim analysis phase 3 study: 66.7%103
NameInventorVaccine typeTarget groupDevelopment statusVaccine efficacy
mRNA-1345ModernamRNA vaccineAdults ≥ 60 yearsPhase 3, submit for approval in the second half of 2023Phase 3 study: 83.7%
RSVPreF3GSKAdjuvanted Protein-based vaccineAdults ≥ 60 yearsFood and Drug Administration (FDA) approval May 2023, European Commission approval June 2023Phase 3 study: overall 82.6%, older adults with underlying medical condition 94.6%101
RSVpreFPfizerProtein-based vaccineAdults ≥ 60 yearsPhase 3, FDA approval, European Commission approval August 2023Interim analysis phase 3 study: 66.7%103

The vaccine candidates are listed in alphabetical order. Vaccination recommendations of the European Society of Cardiology (ESC) guidelines for pulmonary hypertension, chronic heart failure, hypertrophic cardiomyopathy, adult congenital heart disease, acute coronary syndrome, chronic coronary syndrome, cardiovascular disease prevention, peripheral arterial disease, arterial hypertension, diabetes mellitus, and dyslipidaemia.

Table 2
Open in new tab

Respiratory syncytial virus vaccines in phase III clinical trials and in the approval process in older patients

NameInventorVaccine typeTarget groupDevelopment statusVaccine efficacy
mRNA-1345ModernamRNA vaccineAdults ≥ 60 yearsPhase 3, submit for approval in the second half of 2023Phase 3 study: 83.7%
RSVPreF3GSKAdjuvanted Protein-based vaccineAdults ≥ 60 yearsFood and Drug Administration (FDA) approval May 2023, European Commission approval June 2023Phase 3 study: overall 82.6%, older adults with underlying medical condition 94.6%101
RSVpreFPfizerProtein-based vaccineAdults ≥ 60 yearsPhase 3, FDA approval, European Commission approval August 2023Interim analysis phase 3 study: 66.7%103
NameInventorVaccine typeTarget groupDevelopment statusVaccine efficacy
mRNA-1345ModernamRNA vaccineAdults ≥ 60 yearsPhase 3, submit for approval in the second half of 2023Phase 3 study: 83.7%
RSVPreF3GSKAdjuvanted Protein-based vaccineAdults ≥ 60 yearsFood and Drug Administration (FDA) approval May 2023, European Commission approval June 2023Phase 3 study: overall 82.6%, older adults with underlying medical condition 94.6%101
RSVpreFPfizerProtein-based vaccineAdults ≥ 60 yearsPhase 3, FDA approval, European Commission approval August 2023Interim analysis phase 3 study: 66.7%103

The vaccine candidates are listed in alphabetical order. Vaccination recommendations of the European Society of Cardiology (ESC) guidelines for pulmonary hypertension, chronic heart failure, hypertrophic cardiomyopathy, adult congenital heart disease, acute coronary syndrome, chronic coronary syndrome, cardiovascular disease prevention, peripheral arterial disease, arterial hypertension, diabetes mellitus, and dyslipidaemia.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close